Maxim analyst Naz Rahman upgraded Agile Therapeutics to Buy from Hold with a $5 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AGRX:
- Agile Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- Agile Therapeutics sees 2023 net revenue $25M-$30M
- Agile Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
- Agile Therapeutics reports Q2 adjusted EPS ($3.10) vs. ($135.46) last year
- AGRX Earnings Report this Week: Is It a Buy, Ahead of Earnings?